Wipfli Financial Advisors LLC purchased a new position in 10x Genomics, Inc. (NASDAQ:TXG – Get Rating) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 929 shares of the company’s stock, valued at approximately $26,000.
A number of other hedge funds have also made changes to their positions in TXG. Raymond James & Associates lifted its position in shares of 10x Genomics by 19.3% in the first quarter. Raymond James & Associates now owns 53,009 shares of the company’s stock worth $4,032,000 after purchasing an additional 8,570 shares in the last quarter. US Bancorp DE lifted its position in shares of 10x Genomics by 39.6% in the first quarter. US Bancorp DE now owns 9,711 shares of the company’s stock worth $739,000 after purchasing an additional 2,753 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in shares of 10x Genomics by 617.9% in the first quarter. PNC Financial Services Group Inc. now owns 2,046 shares of the company’s stock worth $155,000 after purchasing an additional 1,761 shares in the last quarter. MetLife Investment Management LLC purchased a new stake in shares of 10x Genomics in the first quarter worth approximately $416,000. Finally, BlackRock Inc. lifted its position in shares of 10x Genomics by 14.2% in the first quarter. BlackRock Inc. now owns 9,156,992 shares of the company’s stock worth $696,572,000 after purchasing an additional 1,138,358 shares in the last quarter. 74.34% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several equities analysts recently weighed in on the stock. Morgan Stanley cut their price objective on shares of 10x Genomics from $70.00 to $64.00 and set an “overweight” rating on the stock in a research report on Friday, November 4th. JPMorgan Chase & Co. cut their price objective on shares of 10x Genomics from $65.00 to $55.00 in a research report on Thursday, November 3rd. The Goldman Sachs Group cut their price objective on shares of 10x Genomics from $35.00 to $25.00 and set a “sell” rating on the stock in a research report on Thursday, October 13th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of 10x Genomics in a research report on Tuesday, December 13th. They set a “buy” rating and a $50.00 price objective on the stock. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $51.00.
Insider Transactions at 10x Genomics
10x Genomics Stock Up 5.2 %
Shares of TXG stock opened at $47.33 on Friday. 10x Genomics, Inc. has a 12 month low of $23.81 and a 12 month high of $100.00. The business’s 50 day moving average is $37.44 and its two-hundred day moving average is $35.89. The company has a market cap of $5.42 billion, a PE ratio of -31.86 and a beta of 1.67.
10x Genomics (NASDAQ:TXG – Get Rating) last announced its quarterly earnings results on Wednesday, November 2nd. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.08. 10x Genomics had a negative return on equity of 21.01% and a negative net margin of 33.20%. The company had revenue of $131.10 million for the quarter, compared to the consensus estimate of $129.13 million. During the same quarter last year, the company posted ($0.15) earnings per share. The company’s revenue for the quarter was up 4.6% compared to the same quarter last year. As a group, equities analysts expect that 10x Genomics, Inc. will post -1.6 EPS for the current fiscal year.
About 10x Genomics
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.
- Get a free copy of the StockNews.com research report on 10x Genomics (TXG)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.